New Push to Ban 7‑OH, a Kratom Derivative
What changed
The U.S. Health Secretary, Robert F. Kennedy Jr., has announced a targeted effort to ban 7‑hydroxy‑(7‑OH), a chemically active component of the plant kratom. The move specifically focuses on 7‑OH rather than the broader kratom market.
Source (Wired, 15 Jun 2026): “Both kratom and one of its active components, 7‑OH, have opioid‑like effects and are widely available across the US. As health secretary RFK Jr. aims to get 7‑OH banned, proponents of both are fighting.”
Why it matters
Kratom and 7‑OH are used by a sizable segment of the population for their analgesic and stimulant properties. Because 7‑OH is chemically distinct yet shares the “opioid‑like” profile, a selective ban could reshape the legal landscape for natural‑product supplements, affecting manufacturers, retailers, and users who rely on its effects for self‑medication.
Who is affected
Consumers who purchase kratom or 7‑OH‑containing products for pain relief, mood enhancement, or other self‑treatments.
Vendors and online platforms that list or ship kratom‑derived items across state lines.
Advocacy groups on both sides of the debate, which are expected to mount legal and public‑relations campaigns.
What to watch next
Regulatory filings: Tracking any proposed rulemaking or hearing notices from the Department of Health and Human Services.
Legal challenges: Potential lawsuits from industry coalitions arguing that a narrow ban may overstep federal authority.
Market response: Early shifts in product listings or supply‑chain adjustments as sellers anticipate enforcement.
Original source: Wired, Mon, 15 Jun 2026 11:00 UTC.